Enoxacin inhibits proliferation and invasion of human osteosarcoma cells and reduces bone tumour volume in a murine xenograft model

Osteosarcoma is the most prevalent primary bone malignancy in children and adolescents. Neoadjuvant chemotherapy combined with surgical resection, the current standard treatment of osteosarcoma, is associated with a 5-year survival rate of only ~70%. Therefore, it is necessary to identify new, more...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2020-08, Vol.20 (2), p.1400-1408
Main Authors: Luo, Xuwen, Liu, Xuqiang, Tao, Qianyuan, Yao, Cong, Wang, Fuqiang, Gu, Zhiping, Li, Feilong, Yu, Xiaolong, Zhang, Bin, Fan, Hongxian, Dai, Min, Nie, Tao
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
Antibodies
Apoptosis
B cells
Bone cancer
Cell adhesion & migration
Cell culture
Cell growth
Chemotherapy
EDTA
Enoxacin
Medical prognosis
Membranes
Oncology
Osteosarcoma
Proteins
Sarcoma
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteosarcoma is the most prevalent primary bone malignancy in children and adolescents. Neoadjuvant chemotherapy combined with surgical resection, the current standard treatment of osteosarcoma, is associated with a 5-year survival rate of only ~70%. Therefore, it is necessary to identify new, more effective treatment strategies for patients with this lethal disease. Enoxacin is a highly effective broad-spectrum fluoroquinolone antibiotic with low toxicity. The drug inhibits the growth and metastasis of numerous tumour types, but its efficacy has not been studied in osteosarcoma. This study assessed the antitumour effects of enoxacin in osteosarcoma 143B cells and in a murine tumour xenograft model. Enoxacin inhibited the proliferation, invasion and migration of 143B cells, as well as inducing their apoptosis. These effects were thought to be mediated by downregulation of Bcl-xL, Bxl-2, matrix metalloproteinase (MMP)2 and MMP9 expression. Enoxacin also significantly impaired the growth of bone tumours in nude mice without affecting their liver or kidney function, or blood cell count. Collectively, these results indicate that enoxacin is a promising new drug for osteosarcoma that warrants further evaluation in clinical studies.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2020.11656